Citeline Podcasts

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 December 2024. In this episode: Zepbound bests Wegovy; Novartis and PTC’s Huntingdon’s deal; Vabysmo hopes to ride new listing, data in Asia; Leo Pharma gains momentum; and Immunic’s hopes for MS drug.

https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-FU2EL35AAJBGLIK4EL7KVQRAGU/

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company’s monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.

Pink Sheet reporter and editors discuss potential threats to the COVID-19 vaccine pediatric indications under the Trump Administration (:24), the DOGE commission’s search for spending cuts and its impact on the FDA (12:52), as well as a new 340B rebate pricing model that some pharma companies are implementing to contain the program’s costs (22:52).

More On These Topics From The Pink Sheet

Pediatric COVID Shots, Still Under EUA, Would Be Vulnerable In Anti-Vax HHS: https://insights.citeline.com/pink-sheet/vaccines/pediatric-covid-shots-still-under-eua-would-be-vulnerable-in-anti-vax-hhs-UWJRLYQUCJEWTLC42IFR7X2XFY/

Can US FDA Dodge DOGE? Return To Office Mandate May Be Biggest Hit: https://insights.citeline.com/pink-sheet/legislation/elections/can-us-fda-dodge-doge-return-to-office-mandate-may-be-biggest-hit-5G5SYM3ACNAKLHSSHQL32KJN5Y/

340B Plan B: Pharma Pivots To Rebate Pricing Model After Pharmacy Restrictions Fall Short: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/340b-plan-b-pharma-pivots-to-rebate-pricing-model-after-pharmacy-restrictions-fall-short-M5DTVTFXVZA37IQ6CXMTDW4QMI/

Emma and Summer meet with oncology analysts Neha Anand and David Dahan, to discuss an emerging class of drugs: bispecific antibodies.

In this episode of the In Vivo podcast, Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases, including those stemming from nonsense mutations.

Biopharma is evolving through collaboration, early-phase deal-making and innovation in precision medicine and AI.

At BIO-Europe, Norstella's subject matter experts explored key trends shaping the industry, from market access strategies to sustaining growth through partnerships.

In this episode, Izabela Chmielewska, Kevin Grogan, and Natasha Choukkar discuss takeaways – from advancing personalized treatments to tackling the patent cliff – highlighting how Norstella empowers organizations to navigate complexity and drive innovation.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 29 November 2024. In this episode: Marks on Trump’s threat to FDA; Amgen’s Phase II MariTide data lack clarity; Roche’s Poseida buyout; Roche’s CMO on his biotech lessons; and what Trump 2.0 might mean for India.

https://insights.citeline.com/scrip/podcasts/quick-listen-scrips-five-must-know-things-GIXQTTFOANHRLAWTJEMLY6Z2LI/

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

A preview of the 2024 Scrip Awards and an interview with last year’s Executive of the Year, David Zaccardelli, CEO of Verona Pharma.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 22 November 2024. In this episode: Novo’s semaglutide looks good in NASH; J&J’s psoriasis drug hits multiple Phase III goals; NASH competition gets serious; China dominates APAC and increasingly global trials; and why has M&A decreased in 2024.

https://insights.citeline.com/scrip/podcasts/quick-listen-scrips-five-must-know-things-YDQU2ROM3JAXDD72TMXMOYZGGE/

Link to APAC Clinical Trials White Paper: https://www.citeline.com/en/resources/exploring-the-asia-pacific-clinical-trials-landscape

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Pink Sheet reporter and editors discuss concerns that the incoming administration could try to influence the upcoming FDA user fee reauthorization (:30), as well as the changes Dr. Mehmet Oz, President-elect Donald Trump’s controversial selection of to run the US Centers for Medicare and Medicaid Services, could impose if confirmed (22:35).

#pharma #business

More On These Topics From The Pink Sheet

Trump’s US FDA User Fee Cycle: ‘An Underappreciated Threat’: https://insights.citeline.com/pink-sheet/pathways-and-standards/user-fees/trumps-us-fda-user-fee-cycle-an-underappreciated-threat-GVVSHUIRXBDOHDLWQXHSLC2U4A/

Medicare Price Negotiation Under CMS Chief Oz May See Early 2025 Test: https://insights.citeline.com/pink-sheet/agency-leadership/medicare-price-negotiation-under-cms-chief-oz-may-see-early-2025-test-UOROAUBSE5CWJC65XK6Q5I37SE/

CMS Administrator Nominee Oz Is ‘Communicator’ In Sync With RFK’s Healthy Living Focus: https://insights.citeline.com/pink-sheet/agency-leadership/cms-administrator-nominee-oz-is-communicator-in-sync-with-rfks-healthy-living-focus-CHOJUI4DWVCWRFQMBZXCQYAGB4/